COVALON TECHNOLOGIES LTD (COV.CA) Fundamental Analysis & Valuation

TSX-V:COV • CA22282D3022

Current stock price

1.99 CAD
0 (0%)
Last:

This COV.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. COV.CA Profitability Analysis

1.1 Basic Checks

  • COV had positive earnings in the past year.
  • In the past year COV had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: COV reported negative net income in multiple years.
  • In multiple years COV reported negative operating cash flow during the last 5 years.
COV.CA Yearly Net Income VS EBIT VS OCF VS FCFCOV.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

1.2 Ratios

  • With an excellent Return On Assets value of 2.98%, COV belongs to the best of the industry, outperforming 95.65% of the companies in the same industry.
  • COV has a Return On Equity of 3.70%. This is amongst the best in the industry. COV outperforms 95.65% of its industry peers.
  • COV has a Return On Invested Capital of 1.29%. This is amongst the best in the industry. COV outperforms 95.65% of its industry peers.
Industry RankSector Rank
ROA 2.98%
ROE 3.7%
ROIC 1.29%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COV.CA Yearly ROA, ROE, ROICCOV.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • With an excellent Profit Margin value of 3.10%, COV belongs to the best of the industry, outperforming 95.65% of the companies in the same industry.
  • With an excellent Operating Margin value of 1.59%, COV belongs to the best of the industry, outperforming 95.65% of the companies in the same industry.
  • COV has a Gross Margin of 52.27%. This is amongst the best in the industry. COV outperforms 86.96% of its industry peers.
  • COV's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 1.59%
PM (TTM) 3.1%
GM 52.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.84%
GM growth 5Y9.13%
COV.CA Yearly Profit, Operating, Gross MarginsCOV.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. COV.CA Health Analysis

2.1 Basic Checks

  • COV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • There is no outstanding debt for COV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
COV.CA Yearly Shares OutstandingCOV.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2024 5M 10M 15M 20M 25M
COV.CA Yearly Total Debt VS Total AssetsCOV.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2024 10M 20M 30M 40M

2.2 Solvency

  • COV has an Altman-Z score of 5.39. This indicates that COV is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 5.39, COV belongs to the best of the industry, outperforming 91.30% of the companies in the same industry.
  • The Debt to FCF ratio of COV is 0.32, which is an excellent value as it means it would take COV, only 0.32 years of fcf income to pay off all of its debts.
  • COV has a Debt to FCF ratio of 0.32. This is amongst the best in the industry. COV outperforms 100.00% of its industry peers.
  • COV has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of COV (0.06) is better than 65.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.32
Altman-Z 5.39
ROIC/WACC0.16
WACC8.13%
COV.CA Yearly LT Debt VS Equity VS FCFCOV.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 5.69 indicates that COV has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 5.69, COV belongs to the best of the industry, outperforming 82.61% of the companies in the same industry.
  • COV has a Quick Ratio of 4.29. This indicates that COV is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of COV (4.29) is better than 82.61% of its industry peers.
Industry RankSector Rank
Current Ratio 5.69
Quick Ratio 4.29
COV.CA Yearly Current Assets VS Current LiabilitesCOV.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. COV.CA Growth Analysis

3.1 Past

  • The earnings per share for COV have decreased strongly by -82.26% in the last year.
  • Looking at the last year, COV shows a decrease in Revenue. The Revenue has decreased by -9.04% in the last year.
  • Measured over the past years, COV shows a quite strong growth in Revenue. The Revenue has been growing by 19.43% on average per year.
EPS 1Y (TTM)-82.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-9.04%
Revenue growth 3Y21.83%
Revenue growth 5Y19.43%
Sales Q2Q%-15.64%

3.2 Future

  • The Earnings Per Share is expected to grow by 27.60% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 6.78% on average over the next years.
EPS Next Y3%
EPS Next 2Y43.53%
EPS Next 3Y35.75%
EPS Next 5Y27.6%
Revenue Next Year0.99%
Revenue Next 2Y6.81%
Revenue Next 3Y6.78%
Revenue Next 5Y6.78%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
COV.CA Yearly Revenue VS EstimatesCOV.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M 50M
COV.CA Yearly EPS VS EstimatesCOV.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 0.05 0.1 0.15 0.2

More info and screens

Find the best growth stocksShow best growing peers

6

4. COV.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 66.33, the valuation of COV can be described as expensive.
  • COV's Price/Earnings ratio is rather cheap when compared to the industry. COV is cheaper than 95.65% of the companies in the same industry.
  • COV is valuated expensively when we compare the Price/Earnings ratio to 27.34, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 13.80 indicates a correct valuation of COV.
  • Based on the Price/Forward Earnings ratio, COV is valued cheaply inside the industry as 91.30% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 38.18. COV is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 66.33
Fwd PE 13.8
COV.CA Price Earnings VS Forward Price EarningsCOV.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, COV is valued cheaply inside the industry as 95.65% of the companies are valued more expensively.
  • COV's Price/Free Cash Flow ratio is rather cheap when compared to the industry. COV is cheaper than 95.65% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.4
EV/EBITDA 27.16
COV.CA Per share dataCOV.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of COV may justify a higher PE ratio.
  • A more expensive valuation may be justified as COV's earnings are expected to grow with 35.75% in the coming years.
PEG (NY)22.11
PEG (5Y)N/A
EPS Next 2Y43.53%
EPS Next 3Y35.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. COV.CA Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 7.54%, COV is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.43, COV pays a better dividend. On top of this COV pays more dividend than 100.00% of the companies listed in the same industry.
  • COV's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 7.54%

5.2 History

  • COV is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
COV.CA Yearly Dividends per shareCOV.CA Yearly Dividends per shareYearly Dividends per share 2025 0.05 0.1

5.3 Sustainability

DPN/A
EPS Next 2Y43.53%
EPS Next 3Y35.75%
COV.CA Yearly Income VS Free CF VS DividendCOV.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

More info and screens

Find the best dividend stocksShow peers with best dividend

COV.CA Fundamentals: All Metrics, Ratios and Statistics

COVALON TECHNOLOGIES LTD

TSX-V:COV (4/14/2026, 7:00:00 PM)

1.99

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-26
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.84%
Ins Owner ChangeN/A
Market Cap54.96M
Revenue(TTM)31.54M
Net Income(TTM)977.40K
Analysts84.44
Price Target2.96 (48.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 7.54%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.14%
Min EPS beat(2)-100%
Max EPS beat(2)124.27%
EPS beat(4)2
Avg EPS beat(4)4.61%
Min EPS beat(4)-100%
Max EPS beat(4)124.27%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-22.34%
Min Revenue beat(2)-25.15%
Max Revenue beat(2)-19.53%
Revenue beat(4)0
Avg Revenue beat(4)-15.41%
Min Revenue beat(4)-25.15%
Max Revenue beat(4)-3.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-41.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.33%
Valuation
Industry RankSector Rank
PE 66.33
Fwd PE 13.8
P/S 1.74
P/FCF 8.4
P/OCF 6.94
P/B 2.08
P/tB 2.19
EV/EBITDA 27.16
EPS(TTM)0.03
EY1.51%
EPS(NY)0.14
Fwd EY7.25%
FCF(TTM)0.24
FCFY11.9%
OCF(TTM)0.29
OCFY14.4%
SpS1.14
BVpS0.96
TBVpS0.91
PEG (NY)22.11
PEG (5Y)N/A
Graham Number0.8
Profitability
Industry RankSector Rank
ROA 2.98%
ROE 3.7%
ROCE 1.79%
ROIC 1.29%
ROICexc 3.59%
ROICexgc 4.14%
OM 1.59%
PM (TTM) 3.1%
GM 52.27%
FCFM 20.75%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.84%
GM growth 5Y9.13%
F-Score3
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.32
Debt/EBITDA 1.06
Cap/Depr 146.06%
Cap/Sales 4.35%
Interest Coverage 250
Cash Conversion 549.16%
Profit Quality 669.45%
Current Ratio 5.69
Quick Ratio 4.29
Altman-Z 5.39
F-Score3
WACC8.13%
ROIC/WACC0.16
Cap/Depr(3y)88.92%
Cap/Depr(5y)79.37%
Cap/Sales(3y)2.96%
Cap/Sales(5y)3.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-82.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y3%
EPS Next 2Y43.53%
EPS Next 3Y35.75%
EPS Next 5Y27.6%
Revenue 1Y (TTM)-9.04%
Revenue growth 3Y21.83%
Revenue growth 5Y19.43%
Sales Q2Q%-15.64%
Revenue Next Year0.99%
Revenue Next 2Y6.81%
Revenue Next 3Y6.78%
Revenue Next 5Y6.78%
EBIT growth 1Y-89.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year670.66%
EBIT Next 3Y139.18%
EBIT Next 5Y77.64%
FCF growth 1Y271.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y395.19%
OCF growth 3YN/A
OCF growth 5YN/A

COVALON TECHNOLOGIES LTD / COV.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for COVALON TECHNOLOGIES LTD?

ChartMill assigns a fundamental rating of 6 / 10 to COV.CA.


What is the valuation status for COV stock?

ChartMill assigns a valuation rating of 6 / 10 to COVALON TECHNOLOGIES LTD (COV.CA). This can be considered as Fairly Valued.


What is the profitability of COV stock?

COVALON TECHNOLOGIES LTD (COV.CA) has a profitability rating of 6 / 10.


Can you provide the financial health for COV stock?

The financial health rating of COVALON TECHNOLOGIES LTD (COV.CA) is 8 / 10.


What is the earnings growth outlook for COVALON TECHNOLOGIES LTD?

The Earnings per Share (EPS) of COVALON TECHNOLOGIES LTD (COV.CA) is expected to grow by 3% in the next year.